Literature DB >> 3420267

Choroidal melanoma: I-125 plaque therapy.

J L Bosworth1, S Packer, M Rotman, T Ho, P T Finger.   

Abstract

An iodine-125 eye plaque was used to treat 58 patients with choroidal melanoma. Patients were followed up for a mean of 48.7 months. Fifty patients had medium-sized lesions (height between 3.1 and 8.0 mm and base diameter less than 16.0 mm), and six patients had large lesions. There were 24 lesions less than 3.0 mm from the optic nerve. The average radiation dose to the apex of the tumor was 8,468 cGy (dose rate, 71 cGy per hour). Initial local disease control was achieved in 50 patients (86.2%). One patient with local treatment failure received another plaque treatment, which controlled disease, so the total disease control rate was 87.9%. Only eight patients died of their disease. Complications were similar to those with other treatment methods, but none of the patients in this study developed optic nerve atrophy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3420267     DOI: 10.1148/radiology.169.1.3420267

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  9 in total

1.  Concurrent versus sequential application of ferromagnetic hyperthermia and 125I brachytherapy of melanoma in an animal model.

Authors:  W F Mieler
Journal:  Trans Am Ophthalmol Soc       Date:  1997

2.  Microwave plaque thermoradiotherapy for choroidal melanoma.

Authors:  P T Finger
Journal:  Br J Ophthalmol       Date:  1992-06       Impact factor: 4.638

3.  Radiation-induced optic neuropathy following brachytherapy of uveal melanomas.

Authors:  U Kellner; N Bornfeld; M H Foerster
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-05       Impact factor: 3.117

4.  I-125 brachytherapy for choroidal melanoma photographic and angiographic abnormalities: the Collaborative Ocular Melanoma Study: COMS Report No. 30.

Authors:  H Culver Boldt; B Michele Melia; Judy C Liu; Sandra M Reynolds
Journal:  Ophthalmology       Date:  2009-01       Impact factor: 12.079

5.  Visual outcome after posterior uveal melanoma episcleral brachytherapy including radiobiological doses.

Authors:  David Miguel; Jesús María de Frutos-Baraja; Francisco López-Lara; María Antonia Saornil; Ciro García-Alvarez; Pilar Alonso; Patricia Diezhandino
Journal:  J Contemp Brachytherapy       Date:  2018-04-30

6.  Occupational radiation exposure and glaucoma and macular degeneration in the US radiologic technologists.

Authors:  Mark P Little; Cari M Kitahara; Elizabeth K Cahoon; Marie-Odile Bernier; Raquel Velazquez-Kronen; Michele M Doody; David Borrego; Jeremy S Miller; Bruce H Alexander; Steven L Simon; Dale L Preston; Craig Meyer; Martha S Linet; Nobuyuki Hamada
Journal:  Sci Rep       Date:  2018-07-11       Impact factor: 4.379

7.  The Incidence Risk for Primary Glaucoma and Its Subtypes following Chronic Exposure to Ionizing Radiation in the Russian Cohort of Mayak Nuclear Workers.

Authors:  Tamara V Azizova; Evgeny V Bragin; Maria V Bannikova; Nobuyuki Hamada; Evgeniya S Grigoryeva
Journal:  Cancers (Basel)       Date:  2022-01-25       Impact factor: 6.639

8.  Early SD-OCT diagnosis followed by prompt treatment of radiation maculopathy using intravitreal bevacizumab maintains functional visual acuity.

Authors:  Nisha V Shah; Samuel K Houston; Arnold M Markoe; William Feuer; Timothy G Murray
Journal:  Clin Ophthalmol       Date:  2012-10-29

9.  Stereotactic radiotherapy in the treatment of ocular melanoma: a noninvasive eye fixation aid and tracking system.

Authors:  S M Jaywant; E K Osei; S Ladak
Journal:  J Appl Clin Med Phys       Date:  2003       Impact factor: 2.102

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.